[1] 王银辉, 范菁, 林彬. 低蛋白血症对重症患者抗菌药物剂量调整的研究进展[J]. 抗感染药学, 2022, 19(6):773-777.
[2] ROBERTS J A, PEA F, LIPMAN J. The clinical relevance of plasma protein binding changes[J]. Clin Pharmacokinet, 2013, 52(1):1-8. doi:  10.1007/s40262-012-0018-5
[3] ULLDEMOLINS M, ROBERTS J A, RELLO J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients[J]. Clin Pharmacokinet, 2011, 50(2):99-110. doi:  10.2165/11539220-000000000-00000
[4] 马志超, 孙弋, 赵志刚. 低蛋白血症对重症患者抗菌药物药代动力学和药效学影响的研究进展[J]. 中南药学, 2019, 17(6):903-907.
[5] 彭国茳, 曹毅, 王峰, 等. 基于二维高效液相色谱的头孢哌酮血药浓度测定[J]. 中南药学, 2019, 17(1):105-108.
[6] 《抗菌药物临床试验技术指导原则》写作组. 抗菌药物临床试验技术指导原则[J]. 中国临床药理学杂志, 2014, 30(9):844-856.
[7] HAYASHI Y, LIPMAN J, UDY A A, et al. β-Lactam therapeutic drug monitoring in the critically ill: optimising drug exposure in patients with fluctuating renal function and hypoalbuminaemia[J]. Int J Antimicrob Agents, 2013, 41(2):162-166. doi:  10.1016/j.ijantimicag.2012.10.002
[8] 中国医药教育协会感染疾病专业委员会. 抗菌药物药代动力学/药效学理论临床应用专家共识[J]. 中华结核和呼吸杂志, 2018, 41(6):409-446. doi:  10.3760/cma.j.issn.1001-0939.2018.06.004
[9] GUILHAUMOU R, BENABOUD S, BENNIS Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR)[J]. Crit Care, 2019, 23(1):104. doi:  10.1186/s13054-019-2378-9
[10] 段文琪, 陈明辉, 宋钦, 等. 头孢哌酮钠舒巴坦钠致凝血功能障碍危险因素的meta分析[J]. 临床药物治疗杂志, 2023, 21(9):67-74.
[11] YU Y T, LIU J, HU B, et al. Expert consensus on the use of human serum albumin in critically ill patients[J]. Chin Med J, 2021, 134(14):1639-1654. doi:  10.1097/CM9.0000000000001661